Imagine having a tiny, living version of human organs on a computer chip. Instead of testing new medicines on animals, which often gives wrong results for humans, this system uses real human tissue to see how a drug actually behaves. It's like a high-tech flight simulator for medicine, allowing doctors to test a treatment on a patient's own cells before giving it to them.
Animal testing often fails to predict how drugs will affect humans, leading to expensive failures in clinical trials. There is also a lack of tools to test personalized drug efficacy on patient biopsies for extended periods.
A modular microfluidic platform (CubIX) with stackable modules for gas, flow, and temperature control, along with reusable moulds for disposable components.
If you are a drug discovery firm dealing with high failure rates in clinical trials because animal tests are unreliable — this project developed a multiorgan MPS platform that mimics human physiology to predict toxicity and efficacy more accurately.
If you are a personalized medicine provider dealing with the inability to predict how a specific patient will react to a drug — this project developed a system to cultivate patient biopsies for more than 7 days to test therapeutic strategies before administration.
If you are a cancer research institute dealing with the complexity of simulating circulating metastasis — this project developed a modular platform capable of reconstructing complex tissues including the immune system and vascularization.
Based on available project data, specific pricing is not disclosed, but the platform is designed as a modular system allowing users to customize it according to their budget.
Yes, the project has already started anticipating small scale production and developed reusable moulds for disposable injection mouldings to support scaling.
The technology relies on patent-pending gas mixers (FR2109230) and proprietary microfluidic technologies in gas enrichment and liquid flow (EP3712244, FR3094012, US2020299631).
The solution is designed for seamless adaptability to current workflows and is compatible with all standard multiwell cell cultures and tissues.
The project ran from 2022-11-01 to 2024-08-31, aiming to reach TRL-6 and be investment-ready (IRL-7) for early adopters by the end of the period.
The project is led by a single SME, Cherry Biotech (FR), representing a 100% industry ratio. This lean structure suggests a highly focused commercial drive, utilizing direct partnerships with industry giants like Sanofi and research centers like Gustave Roussy Institut for validation rather than a large academic consortium.
Contact Cherry Biotech in France regarding the CubIX Platform and IDEFIX modular MPS.
Contact us to identify licensing opportunities for the IDEFIX microfluidic patents.
